NCT04209218Recruiting
Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 31 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1988 (estimated)
- First submitted
- 17 Dec 2019
- Start date
- 7 Apr 2020
- Primary completion date
- Dec 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Lung cancer
- NCT number
- NCT04209218
What you commit to
- Study type: Interventional
- Planned participants: 1988
- From 7 Apr 2020 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.
- Recurrent or metastatic lung cancer.
- History of cancer or complicated with cancer in other organs.
- Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.
- Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg); or requirement of vasopressors to maintain blood pressure.
- Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.
- Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).
Other
- Any other circumstances considered unsuitable for study participation by attending physicians or investigators.
Who the study is looking for
- Aged \>50 years but \<90 years.
- Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \>2 hours.
- Agree to participate in this study and sign the informed consent.
Age in the registry: 50 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.